Evidence map›Paper›PMID 40921831›Full record

ArticleJournal of cancer research and clinical oncology2025

Inhibition of dipeptidyl peptidase 9 improves sorafenib sensitivity by inducing ferroptosis in hepatocellular carcinoma.

Qing Li, Yang Wang, Jun Zou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qing LiCollege of Pharmacy, Hubei College of Chinese Medicine, Jingzhou, 434020, China.
Yang WangDepartment of Adult Internal Medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, No. 745 Wuluo Road, Wuhan, 430070, China. wangyang_hbfy@163.com.
Jun ZouDrug Inspection Laboratory, Jingzhou Institute for Food and Drug Control, Jingzhou, 434000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDipeptidyl peptidase 9 (DPP9) not only regulates tumor progression and drug sensitivity, but also modifies oxidative stress mediated ferroptosis. This study aimed to investigate the effect of DPP9 inhibition on sorafenib sensitivity and its interaction with ferroptosis in hepatocellular carcinoma (HCC).

methodsTwo HCC cell lines (Huh7 and MHCC-97H) were transfected with DPP9 siRNA, followed by detection of reactive oxygen species (ROS), ferrous iron (Fe

resultsInhibition of DPP9 improved sorafenib sensitivity reflected by a lower sorafenib IC

conclusionInhibition of DPP9 improves sorafenib sensitivity by promoting ferroptosis in HCC, which provides novel evidence for DPP9 as an HCC treatment target synergizing with sorafenib.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularFerroptosisLiver NeoplasmsSorafenibCell Line, TumorCyclohexylaminesDrug Resistance, NeoplasmHumansPhenylenediaminesReactive Oxygen SpeciesRNA, Small InterferingAntineoplastic AgentsCyclohexylaminesferrostatin-1PhenylenediaminesReactive Oxygen SpeciesRNA, Small InterferingSorafenibDipeptidyl peptidase 9FerroptosisHepatocellular carcinomaOxidative stressSorafenib sensitivity

Identifiers

PMID40921831
PMCPMC12417342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.